TrialScope Adds Seven Additional Languages to Trial Results Summaries Portal
JERSEY CITY, N.J., July 18, 2017 – TrialScope, a global company in patient-centric clinical trial transparency and compliance solutions, announced that the Trial Results Summaries Portal now supports trial summaries in English and seven additional languages: Chinese, French, German, Japanese, Polish, Russian, and Spanish.
The Trial Results Summaries Portal, launched in February 2017, is designed to improve patient and trial participant access to trial results summaries (also known as lay language summaries) by allowing immediate global web access to trial results summaries.
“Clinical Trial participants and patients want to access to research results, and we are committed to supporting and expanding the transparency efforts of trial sponsors,” said Mark Heinold, TrialScope’s Chief Executive Officer. “We understand the importance of making this information available to trial participants around the world in an accurate and timely manner, and the additional language support is the natural progression of these efforts.”
The Center for Information and Study on Clinical Research Participation (CISCRP) is an independent non-profit organization that specializes in delivering trial results summaries in various formats to patients. Jill McNair, CISCRP’s Senior Director of Patient Engagement, commented, “Communicating trial results summaries in clinical trial participant’s native language is an important step in engaging trial participants, patients and the public while arming a broader audience with important health information.”
The Trial Results Summaries Portal is available at www.trialsummaries.com. Clinical trial sponsors may contact TrialScope to learn more about the benefits, features and pricing of the solution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
